Today (August 18) evening, Juzi Biotech released its results for the first half of 2026:

During the period, sales revenue was approximately 2.92 billion yuan, down 6.3% year-on-year; net profit was approximately 940 million yuan, down 20.5% year-on-year; adjusted net profit was approximately 950 million yuan, down 21.5% year-on-year.

However, judging from the month-on-month performance, Giant Biotech's performance is gradually getting out of the trough in the second half of last year-revenue in the first half of this year increased by 21.3% month-on-month (compared with the second half of last year), and net profit attributable to the parent company increased by 28.3% month-on-month, showing a momentum of recovery.

As of today's close, Juzi Biotech's total market value was 29.83 billion Hong Kong dollars (approximately RMB 25.645 billion). In the past year, its market value has evaporated by 31.322 billion Hong Kong dollars (approximately RMB 26.928 billion), a drop of 51.22%.

Revenue from the broadcasting terminal has dropped

Looking back at 2025 and before, Giant Biotech was once in a growth channel.

From the first half of 2023 to the first half of 2025, Giant Biotech's revenue increased from 1.606 billion yuan to 3.113 billion yuan, and its net profit increased from 667 million yuan to 1.182 billion yuan. During the period, the year-on-year growth rate has remained in double digits, with the highest increase in revenue reaching 63.03%, and the highest increase in net profit reaching 52.53%.

A summary of Juzi Biotech's performance in recent years is obtained from Oriental Fortune. com

Looking at the whole year, revenue in 2024 and 2025 will be stable at more than 5.5 billion yuan, and net profit will remain at around 2 billion yuan.

Entering the first half of 2026, Giant Biotech's performance showed a slight correction: sales revenue was approximately 2.92 billion yuan, down 6.3% year-on-year; net profit was approximately 940 million yuan, down 20.5% year-on-year.

This trend has long been foreboded-after the public opinion crisis in the second half of 2025, Juzi Biotech's performance has been significantly under pressure. Current revenue fell 19.77% year-on-year to 2.406 billion yuan, and net profit fell 32.05% year-on-year to 733 million yuan.

Juzi Bio reported that the decline in revenue was attributed to fluctuations in the professional skin care product line. Specifically, due to increased competition in the industry and the company's proactive optimization of sales structures, revenue from live broadcasts declined for functional skin care products; revenue from medical devices fell due to changes in the operating environment of offline channels and intensified competition.

In this regard, Giant Biotech has adopted dual coping strategies: on the one hand, it has increased the construction of brand content assets, strengthened the layout of self-operated channels, and promoted year-on-year growth in self-operated revenue; on the other hand, it relies on the strong product power of star new products to accelerate the volume, and continues to improve the product matrix, effectively hedging some of the downward pressure on sales.

In terms of month-on-month performance, Giant Biotech is gradually getting out of the trough-revenue in the first half of this year increased by 21.3% compared with the second half of last year, and net profit attributable to the parent company increased by 28.3% month-on-month.

Based on current trends, Juzi Bio's annual revenue this year may stabilize above 5 billion yuan.

But Fumei fell, but it was expected to rise

In terms of brands, the core brand Kefumei achieved sales revenue of 2.347 billion yuan in the first half of 2026, a year-on-year decrease of 7.7%, accounting for 80.4% of total revenue. The reason for the decline was that the revenue of Daowang was affected by intensified competition and sales structure adjustments.

Looking back on the past five years, Kefu reached its peak in 2024, with revenue of 4.542 billion yuan. This year is expected to stabilize at more than 4 billion yuan.

Kolykin's performance was relatively stable, recording revenue of 499 million yuan in the first half of the year, which was basically the same as the same period in 2025, accounting for 17.1% of total revenue.

In the past two years, Kelijin has continued to grow. Its revenue in 2025 will reach 918 million yuan, which is impacting the scale of 1 billion. However, judging from the current trend, it is still difficult to break through.

It is worth mentioning that other brands recorded revenue of 64.5 million yuan in the first half of this year, an increase of 11.0% compared with the same period in 2025, accounting for 2.2% of the total revenue during the reporting period. This increase is due to the expansion of pre-existing brands across all channels.

Kemei has opened 32 experience stores

In terms of channels, in the first half of this year, Juzi Biotech's direct sales channel revenue was approximately 2.23 billion yuan, accounting for 76.6%; distribution channel revenue was approximately 680 million yuan, accounting for 23.4%.

Specifically, online direct sales revenue through DTC stores was 1.777 billion yuan, a year-on-year decrease of 2.2%, accounting for 60.9% of total revenue. It was mainly affected by the decline in revenue from DBT; however, the company continued to strengthen multi-platform refined operations, and self-operated revenue achieved year-on-year growth.

Online direct sales revenue to e-commerce platforms was 335 million yuan, a year-on-year decrease of 14.5%, accounting for 11.5% of total revenue, mainly due to the optimization of Jingdong channel inventory turnover and stocking pace.

Offline direct sales revenue was 123 million yuan, a year-on-year increase of 4.2%, accounting for 4.2% of total revenue. The growth came from the development of new high-quality channels and the strengthening of store marketing, terminal display and personnel training. At the same time, the company continues to open Fumei brand experience stores in Chongqing, Qingdao, Shenzhen and other cities to increase sales contacts.

Dealer channel revenue was 683 million yuan, a year-on-year decrease of 13.2%, accounting for 23.4% of total revenue. Mainly due to weak offline terminal consumption, dealers tend to be cautious in ordering.

In terms of channel layout, online and offline channels. As of the end of the reporting period, Juzi Biotech's brands and products have entered approximately 1700 public hospitals, approximately 3500 private hospitals and clinics, more than 130,000 chain pharmacies and approximately 6000 CS/KA stores. In the core business district, a total of 32 Kefu brand experience stores have been launched, and a total of 10 Kelijin brand experience stores have been launched. In overseas markets, Kefumei launches Malaysia 2026 ASIATOP MUSIC FE

Despite SKIGIN's public statement that this action is merely an adjustment of the cooperative relationship with the operator, the temporary closure of the store, followed by new planning and operational arrangements, this move still reflects the realistic difficulties of Jushu Biology in cultivating multiple brands.

To break through the bottleneck, Jushu Biology is accelerating its strategic transformation. In 2026, it explicitly proposed the "Dual Beauty Strategy" and increased investment in the medical beauty track; from October 2025 to June 2026, a total of 4 Class III medical device certificates were approved; in June 2026, Keli Jin launched its first recombinant collagen facial injection "Xinsheng 753 Collagen Needle," officially entering the professional medical beauty field from daily beauty. At the same time, the financial report for the first half of this year shows that the Keli Jin brand is gradually growing into a promising new growth point.

Overall, the growth momentum of Jushu Biology is still highly concentrated on the two major brands. Whether the new strategy can successfully open up a second growth curve remains to be tested by the market.

In the financial report, Jushu Biology pointed out that looking forward to the second half of 2026, the company will adhere to the strategic determination of long-termism, continuously deepen the layout of technological research and development, accelerate the industrialization of innovative raw materials and Class III medical devices; simultaneously promote the deepening of the value of the major brands and the breakthrough of the cognitive barriers of the whole population, covering the entire lifecycle of the product ecosystem; deeply cultivate the self-operated territory online, and strengthen the network from medical institutions to retail terminals offline, continuously upgrading and incubating new brands and expanding the global layout.

This article explores Aromatherapy, Fragrance, Perfume, Essential Oil, Fireless Aromatherapy, Aromatherapy Candle, Vine Incense Stick, Home Fragrance, Natural Aromatherapy, Diffuser, sharing the latest industry insights and offering practical references for enthusiasts.

Source: 品观网 (https://www.pinguan.com/)

This article is reproduced from the original source for information sharing only. If it infringes any copyright, please contact us and we will remove it promptly.

© 2026 CeresMall | www.CeresMall.com